Acute undifferentiated leukemia
MONDO:0020321A rare acute leukemia of ambiguous lineage in which the blasts do not express markers specific to myeloid or lymphoid lineage.
Also known as: acute myeloid leukemia, minimal differentiation, FAB M0, acute undifferentiated leukemia, leukaemia stem cell, leukemia stem cell, stem cell acute leukaemia, stem cell acute leukemia, stem cell leukaemia, stem cell leukemia
3117 clinical trials for this condition and its sub-types, 27 tagged with Acute undifferentiated leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise in preventing deadly transplant complication
Disease control CompletedThis study tested whether adding the drug abatacept to standard medications (calcineurin inhibitor and methotrexate) could better prevent severe acute graft-versus-host disease (aGVHD) after a stem cell transplant from an unrelated donor. A total of 186 participants aged 6 and ol…
Phase 2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Half-Matched stem cell transplant shows promise for older blood cancer patients
Disease control CompletedThis study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo may make bone marrow transplants safer for blood cancer patients
Disease control CompletedThis early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…
Phase 1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC